IP Verse

Combinations Of A Muscarinic Receptor Antagonist And A Beta-2 Adrenoreceptor Agonist - EP2506844

The patent EP2506844 was granted to Glaxo Group on Dec 20, 2017. The application was originally filed on Nov 29, 2010 under application number EP10781527A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2506844

GLAXO GROUP
Application Number
EP10781527A
Filing Date
Nov 29, 2010
Status
Opposition Rejected
Jun 7, 2024
Grant Date
Dec 20, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SIMA PATENT VE LISANSLAMA HIZMETLERI LTDSTISep 20, 2018GILL JENNINGS & EVERYADMISSIBLE
BREUERSep 19, 2018BREUERADMISSIBLE
TEVA PHARMACEUTICALSSep 17, 2018ELKINGTON AND FIFEADMISSIBLE

Patent Citations (23) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONGB2242134
DESCRIPTIONWO0212265
DESCRIPTIONWO03024439
DESCRIPTIONWO03061743
DESCRIPTIONWO2005104745
DESCRIPTIONWO2007012871
DESCRIPTIONWO2007068896
DESCRIPTIONWO9421229
DESCRIPTIONWO9834596
INTERNATIONAL-SEARCH-REPORTWO03024439
INTERNATIONAL-SEARCH-REPORTWO2005037280
INTERNATIONAL-SEARCH-REPORTWO2005104745
INTERNATIONAL-SEARCH-REPORTWO2005115463
INTERNATIONAL-SEARCH-REPORTWO2010097114
INTERNATIONAL-SEARCH-REPORTWO2010097115
OPPOSITIONUS7488827
OPPOSITIONWO03024439
OPPOSITIONWO2005037280
OPPOSITIONWO2005104745
OPPOSITIONWO2005115463
OPPOSITIONWO2009090010
OPPOSITIONWO2010097114
OPPOSITIONWO2010097115

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- LAINE, DRAMANE I. ET AL, "Discovery of Novel 1-Azoniabicyclo[2.2.2]octane Muscarinic Acetylcholine Receptor Antagonists", JOURNAL OF MEDICINAL CHEMISTRY , 52(8), 2493-2505 CODEN: JMCMAR; ISSN: 0022-2623, (2009), XP002621866 [Y] 1-68 * pages 2496-8; table 2 *
OPPOSITION- Anonymous, "Eklira®", Annex I: Summary of product characteristics (SmPC) European Medicines Agency, (20120730), XP002780227
OPPOSITION- Anonymous, "History of Changes for Study: NCT00976144 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects (DB2113208)", clinicaltrials.gov, (20090911), pages 1 - 5, clinicaltrials.gov, URL: https://clinicaltrials.gov/ct2/history/NCT00976144?A=1&B=1&C=merged#StudyPageTop, (20220715), XP055943101
OPPOSITION- Anonymous , "Umeclidinium bromide | C29H34BrNO2", PubChem COMPOUND, (20061026), Database accession no. CID 11519069, XP055943090
OPPOSITION- Anonymous , "Vilanterol | C24H33Cl2NO5", Pubchem COMPOUND, (20061025), Database accession no. CID 10184665, XP055943094
OPPOSITION- EMA, "ANORO®", Summary of product characteristics (SmPC) European Medicines Agency
OPPOSITION- FDA, "FDA approval labelling for Tudorza®", Highlights of prescribing information US Food and Drug Administration, XP002780228
OPPOSITION- GINA teams, "The global strategy for asthma management and prevention", Global Initiative for Asthma, (20090000), XP055520525
OPPOSITION- GOLD teams, "The global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease", Executive Summary Global Initiative for Chronic Obstructive Lung Disease, (20090000), XP055520517
OPPOSITION- PETER J. BARNES, "ABC OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: FUTURE TREATMENTS", BMJ, (20060729), vol. 333, pages 246 - 248, XP009083676
OPPOSITION- P. J. BARNES et al., "The Pharmacological Properties of Tiotropium", Chest, (20000200), vol. 117, no. 2, pages 63S - 66S, XP055520530
OPPOSITION- X.M. ZENG et al., Particulate interactions in dry powder formulations for inhalation, London, Taylor & Francis, (20010000), pages 156 - 159, XP055520504
OPPOSITION- P. JONES, "Aclidinium Bromide Twice Daily for the Treatment of Chronic Obstructive Pulmonary Disease: A Review", Advanced Therapeutics, (20130400), vol. 30, no. 4, pages 354 - 368, XP002780229
OPPOSITION- CAZZOLA et al., "The effective treatment of COPD: Anticholinergics and what else?", Drug Discovery Today: Therapeutic Strategies, (20060000), vol. 3, no. 3, pages 277 - 286, XP005777432
OPPOSITION- Gross, N.J., "Anticholinergic agents in asthma and COPD", European Journal of Pharmacology, Elsevier science, NL, NL , (20060308), vol. 533, no. 1-3, doi:10.1016/j.ejphar.2005.12.072, ISSN 0014-2999, pages 36 - 39, XP028028951
OPPOSITION- Dramane I Lainé et al., "Discovery of Novel 1-Azoniabicyclo[2.2.2]octane Muscarinic Acetylcholine Receptor Antagonists", J. Med. Chem., (20090000), vol. 52, pages 2493 - 2505, XP002691510
OPPOSITION- Dramane I. Laineì, Brent McCleland, Sonia Thomas, Christopher Neipp, Brian Underwood, Jeremy Dufour, Katherine L. Widdowson, Michael R. Palovich, Frank E. Blaney, James J. Foley, Edward F. Webb, Mark A. Luttmann, Miriam Burman, Kristen Belmonte, and Michael Salmon, "Discovery of Novel 1-Azoniabicyclo[2.2.2]octane Muscarinic Acetylcholine Receptor Antagonists", Journal of Medicinal Chemistry, American Chemical Society, US, US , (20090423), vol. 58, no. 8, doi:10.1021/jm801601v, ISSN 0022-2623, pages 2493 - 2505, XP002691510
OPPOSITION- D. LAINE et al., "Discovery of Novel 1-Azoniabicyclo[2.2.2]octane Muscarinic Acetylcholine Receptor Antagonists", Journal of Medicinal Chemistry, (20090000), vol. 52, no. 8, pages 2493 - 2505, XP002621866
OPPOSITION- M Cazzola, M G Matera, "Novel long-acting bronchodilators for COPD and asthma", British Journal of Pharmacology, Nature Pub. Group, etc., (20081001), vol. 155, no. 3, doi:10.1038/bjp.2008.284, ISSN 00071188, pages 291 - 299, XP055104106
OPPOSITION- Schelfhout et al., "Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study", British Journal of Clinical Pharmacology, (20100412), vol. 69, no. 5, pages 458 - 464, XP009504914
OPPOSITION- M Cazzola, Et Al, "Emerging inhaled bronchodilators: an update", Eur Respir J, (20090101), vol. 34, doi:10.1183/09031936.00013109, pages 757 - 769, XP055697899
OPPOSITION- Cazzola M, "Current opinion: Pharmacological approaches in asthma and COPD", Breathe, (20090901), vol. 6, no. 1, doi:10.1183/18106838.0601.024, ISSN 1810-6838, pages 24 - 35, XP055943110
OPPOSITION- Gupta Abhay, Hamad Mazen L., Tawakkul Mobin, Sayeed Vilayat A., Khan Mansoor A., "Difference in the Lubrication Efficiency of Bovine and Vegetable-Derived Magnesium Stearate During Tabletting", AAPS PharmSciTech, (20090602), vol. 10, no. 2, doi:10.1208/s12249-009-9229-y, pages 500 - 504, XP055943118
OPPOSITION- CAZZOLA M; ET AL, "Ultra long-acting beta2-agonists in development for asthma and chronic obstructive pulmonary disease", Expert Opin. Investig. Drugs, (20050000), vol. 14, no. 7, pages 775 - 783, XP003026042

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents